logo
  • Über uns
    • Über uns
    • Führungsteam
    • Unsere Verantwortung
    • Kollaborationen
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Analysten-Coverage
    • Hauptversammlung
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Natural mRNA

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines


by Sovereign

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals


by Sovereign

A development, that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs


by Sovereign